HBM Holdings Limited (HKG:2142)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
8.63
-0.07 (-0.80%)
Apr 2, 2025, 1:43 PM HKT

HBM Holdings Company Description

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas.

The company has developed the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats.

It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4; and HBM1020, human monoclonal antibody generated from harbour mice platform targeting B7H7.

The company is also developing HBM9378 for the treatment of Asthma; and HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014 for the treatment of solid tumors.

It operates in Mainland China, the United States, Europe, and internationally. The company has collaborations with AstraZeneca, Pfizer, Hualan Genetic Engineering Co., Ltd., Beigene, Ltd., Duality Biotherapetuics, Inc., Mythic Therapeutics, Washington University, Evive Biotech.

HBM Holdings Limited was incorporated in 2016 and is based in Suzhou, the People’s Republic of China.

HBM Holdings Limited
Country Cayman Islands
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 177
CEO Jingsong Wang

Contact Details

Address:
Building A3
Suzhou, 215123
China
Phone 86 51 2657 90025
Website harbourbiomed.com

Stock Details

Ticker Symbol 2142
Exchange Hong Kong Stock Exchange
Fiscal Year January - December
Reporting Currency USD
ISIN Number KYG4403H1002
SIC Code 2836

Key Executives

Name Position
Dr. Jingsong Wang M.D., Ph.D. Founder, Chairman and Chief Executive Officer
Dr. Yiping Rong Ph.D. Chief Scientific Officer and Executive Director
Youchen Chen Vice President, Head of Finance and Investor Relations
Dr. Ian Y. Liu Senior Vice President and Global Head of Legal
Dr. Peter F. Moesta Ph.D. Member of Scientific Advisory Board and Chief CMC Advisor
Dr. Xiaolu Tao Chief Development Officer
Dr. Steve Arkinstall DPhil Chief Scientific Advisor
Dr. Ben Chih Ph.D. Chief Scientific Officer of Neurosciences - Harbour BioMed US
Dr. Michael Lee Ph.D. Senior Vice President and Head of Biometrics
Amy Jiang Vice President, Chief of Staff and Head of Quality Department